Primaxin
Product Images NDC 0006-3551

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Primaxin (NDC 0006-3551). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Merck Sharp & Dohme Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Primaxin Iv 01)

Chemical structure of the active ingredient in PRIMAXIN IV, as shown in the image, representing its molecular arrangement including rings, functional groups, and atoms with water (H2O) indicated.*

FDA Label Image

Chemical Structure (Primaxin Iv 02)

Chemical structure of the active ingredient in PRIMAXIN IV, showing its molecular framework including functional groups such as an amino group, carboxyl group, and a thioether linkage.*

FDA Label Image

Principal Display Panel 250 mg Bottle Label (Primaxin Iv 03)

Label for PRIMAXIN I.V. 250 mg injection, containing imipenem and cilastatin for injection. The label states 'IMIPENEM 250 mg (Anhydrous Equivalent)' and 'CILASTATIN EQUIVALENT 250 mg'. It is a single-dose vial for intravenous use only, not for direct infusion. Labeler is Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ. NDC 0006-3514-58 is printed on the label.*

FDA Label Image

Principal Display Panel 500 mg Bottle Label (Primaxin Iv 04)

Label for PRIMAXIN I.V. 500 mg vial injection by Merck Sharp & Dohme LLC. The label indicates each vial contains 500 mg imipenem, 500 mg cilastatin, and 20 mg sodium bicarbonate as a buffer. It is a single-dose vial for intravenous use only, not for direct infusion. The package contains 25 vials. The NDC is 0006-3516-59.*

FDA Label Image

Single-dose Add-vantage Vial 250 mg (Primaxin Iv 05)

Label for PRIMAXIN IV 250 mg/250 mg single-dose ADD-Vantage vial containing imipenem and cilastatin for injection. The label includes warnings for single-dose use only and not for direct infusion. Manufactured by Merck Sharp & Dohme LLC and Abbott Laboratories.*

FDA Label Image

Single-dose Add-vantage Vial 500 mg (Primaxin Iv 06)

Label for PRIMAXIN I.V. 500 mg/100 mL, an injection containing imipenem and cilastatin. The label identifies the product as a single-dose ADD-Vantage vial with a NDC of 0006-3552-59. The labeler is Merck Sharp & Dohme LLC. It includes cautions stating the vial is for IV use only and not for direct infusion.*

FDA Label Image

Primaxin Iv 07

Label for PRIMAXIN I.V. injection, 500 mg strength. The label states the active ingredients as imipenem and cilastatin for injection, with each vial containing 500 mg imipenem and 500 mg cilastatin. It is described as a single-dose vial for intravenous use only, not for direct infusion. Manufactured by Merck Sharp & Dohme LLC, USA. The NDC number 0006-3516-59 is visible on the label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.